Chuyển sang chế độ ngoại tuyến với ứng dụng Player FM !
132: Aiding Diagnosis of Synucleinopathies Through SAAmplify-aSYN Biomarker Test
Fetch error
Hmmm there seems to be a problem fetching this series right now. Last successful fetch was on November 14, 2025 11:11 ()
What now? This series will be checked again in the next day. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.
Manage episode 460374190 series 3340456
In this episode, Russ Lebovitz, MD, PhD, chief executive officer and cofounder of Amprion, discussed the company's SAAmplify-aSYN biomarker test, a first-in-class qualitative laboratory developed test and the only seed amplification assay available to aid in the diagnosis of synucleinopathies such as Parkinson disease (PD) and multiple system atrophy (MSA). Lebovitz provided insight on the new technology and its remarkable accuracy in identifying underling a-synuclein pathology using fluorescence changes. He gave a complete overview of the notable study published in The Lancet Neurology that further tested and validated the assay among a heterogenous group of synucleinopathies. Furthermore, he provided clinical context on the feasibility of the assay, the potential for clinical use, and the continued validation needed.
Looking for more movement disorder discussion? Check out the NeurologyLive® Movement disorder clinical focus page.
Episode Breakdown:
- 1:05 – Overviewing mechanistic function of SAAmplify-aSYN biomarker test, its purpose, and how it came about
- 7:50 – Results from the published study; ways the fluorescence-based amplification method could distinguish MSA from PD and Lewy body dementia
- 16:25 – Neurology News Minute
- 18:30 – Therapeutic feasibility of the assay in clinical settings and the next steps in validation
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
Axsome to Submit NDA for AXS-05 in Alzheimer Agitation Following Positive Phase 3 Trials
FDA Clears IND for Trial Assessing Gene Therapy SGT-212 in Friedreich Ataxia
FDA Grants Fast Track Designation to Anti-Tau Therapy Posdinemab
Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
174 tập
Fetch error
Hmmm there seems to be a problem fetching this series right now. Last successful fetch was on November 14, 2025 11:11 ()
What now? This series will be checked again in the next day. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.
Manage episode 460374190 series 3340456
In this episode, Russ Lebovitz, MD, PhD, chief executive officer and cofounder of Amprion, discussed the company's SAAmplify-aSYN biomarker test, a first-in-class qualitative laboratory developed test and the only seed amplification assay available to aid in the diagnosis of synucleinopathies such as Parkinson disease (PD) and multiple system atrophy (MSA). Lebovitz provided insight on the new technology and its remarkable accuracy in identifying underling a-synuclein pathology using fluorescence changes. He gave a complete overview of the notable study published in The Lancet Neurology that further tested and validated the assay among a heterogenous group of synucleinopathies. Furthermore, he provided clinical context on the feasibility of the assay, the potential for clinical use, and the continued validation needed.
Looking for more movement disorder discussion? Check out the NeurologyLive® Movement disorder clinical focus page.
Episode Breakdown:
- 1:05 – Overviewing mechanistic function of SAAmplify-aSYN biomarker test, its purpose, and how it came about
- 7:50 – Results from the published study; ways the fluorescence-based amplification method could distinguish MSA from PD and Lewy body dementia
- 16:25 – Neurology News Minute
- 18:30 – Therapeutic feasibility of the assay in clinical settings and the next steps in validation
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
Axsome to Submit NDA for AXS-05 in Alzheimer Agitation Following Positive Phase 3 Trials
FDA Clears IND for Trial Assessing Gene Therapy SGT-212 in Friedreich Ataxia
FDA Grants Fast Track Designation to Anti-Tau Therapy Posdinemab
Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
174 tập
Tất cả các tập
×Chào mừng bạn đến với Player FM!
Player FM đang quét trang web để tìm các podcast chất lượng cao cho bạn thưởng thức ngay bây giờ. Đây là ứng dụng podcast tốt nhất và hoạt động trên Android, iPhone và web. Đăng ký để đồng bộ các theo dõi trên tất cả thiết bị.